ArticleNanomedicine (London, England)2021
Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment
Article in Nanomedicine (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 77 citations in OpenAlex.
- Nanomaterial Strategies for Pulmonary Delivery of Immunotherapeutics in Lung Cancer Treatment.Advanced healthcare materials · 2026Review
- Nanoparticles for antiviral nucleotide analogs: approaches and analytical challenges.Journal of virology · 2026Review
- Unlocking the potential of remdesivir: innovative approaches to drug delivery.Drug delivery and translational research · 2025Review
- Formulation and In-Vitro Testing of Nebulized Camostat Mesylate Loaded Nanoliposomes for the Treatment of SARS-CoV- 2 Infection.AAPS PharmSciTech · 2025Article
- Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections.Life science alliance · 2025Article
- Recent Advancements in the Delivery of Therapeutic Agents Targeting RNA-dependent RNA Polymerase of SARS-CoV-2.Current medicinal chemistry · 2025Review
- Nanovesicles as Potential Carriers for Delivery of Antiviral Drugs: A Comprehensive Review.Current drug delivery · 2025Review
- A novel nanocomposite drug delivery system for SARS-CoV-2 infections.Nanoscale advances · 2024Article
- Remdesivir-Loaded Nanoliposomes Stabilized by Chitosan/Hyaluronic Acid Film with a Potential Application in the Treatment of Coronavirus Infection.Neurology international · 2023Article
- Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection.Pharmaceutics · 2023Article
- Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections.Pharmaceutical research · 2023Review
- Localized delivery of nanomedicine and antibodies for combating COVID-19.Acta pharmaceutica Sinica. B · 2023Review
- Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.Drug delivery and translational research · 2023Review
- Arginine-Coated Nanoglobules for the Nasal Delivery of Insulin.Pharmaceutics · 2023Article
- Recent advances in nanoparticle applications in respiratory disorders: a review.Frontiers in pharmacology · 2023Review
- Article
- Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?Biomedicines · 2022Review
- Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.Pharmaceutical research · 2022Article
- Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.Journal of pharmaceutical sciences · 2022Review
- A systemic review on liquid crystals, nanoformulations and its application for detection and treatment of SARS - CoV- 2 (COVID - 19).Journal of molecular liquids · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.